Dr. Hovinga is recognized as an expert in pediatric pharmacology and pediatric clinical trial conduct. He has held appointments with the FDA’s Peripheral and Central Nervous System Advisory Committee and key roles in pediatric interventional clinical trials and neuroprotective drug pharmacology National Institutes of Health projects.
Dr. Hovinga’s understanding of developmental pharmacology and pediatric medical conditions has made him a frequent journal reviewer and invited speaker at national organizational meetings. He is also an active board member and advocate in many pediatric rare medical conditions and is currently a clinical associate professor at the University of Texas at Austin.
Dr. Hovinga earned his B.S. and PharmD from Creighton University in Omaha, Nebraska. He completed a residency and fellowship in pediatric pharmacotherapy with emphasis in pediatric neuroscience at the University of Tennessee, Memphis, Le Bonheur Children’s Medical Center. He completed a second fellowship at the FDA Office of Clinical Pharmacology and a Master of Science in epidemiology at the University of Tennessee Health Science Center. He has additional training in outcomes research from MD Anderson Cancer Center.